HPLC purity
Reverse-phase HPLC with UV detection; ≥99% area-purity target on each production lot.
PeptiOEM · Catalog · Retatrutide
GLP-1 family · Engine 2 (OUS only)
Retatrutide OEM supply.
OUS markets & research only.
Lyophilized retatrutide (triple GLP-1 / GIP / glucagon receptor research compound) for OUS (non-US) distribution, research labs, and private-label brand evaluation outside the United States. 99%+ HPLC purity, per-batch COA + MS.
!
OUS & research only — not for US compounding under FDA 2026 proposal
On 2026-04-30 the FDA proposed removing GLP-1 medications from the 503B bulks list, with public comment open through 2026-06-29. Pending finalization, this compound is positioned for OUS (non-US) distribution markets, research, and private-label brand evaluation only. Read the GLP-1 2026 update →
Lot RET-10HPLC ≥ 99%MS confirmed5 / 10 / 15 / 20 mg
Vial illustrations reflect supplied lyophilized format. Lot codes are sample identifiers; production lots carry their own batch references.
| Compound | Retatrutide |
|---|---|
| Class | Triple GLP-1 / GIP / glucagon receptor agonist (research) |
| Molecular weight | ≈ 4731 g/mol |
| Form | Lyophilized powder, sterile glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 5 mg, 10 mg, 15 mg, 20 mg |
| Documentation | COA + HPLC + MS, per-batch lot file |
| Distribution scope | OUS markets & research only |
| Storage | 2–8 °C protected from light; long-term −20 °C |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 100 vials | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat (OUS) | 2,000+ vials | 21–28 days, scheduled |
All retatrutide quotes require a destination country and buyer track. Inquiries from US compounding facilities are answered with the 503B bulks list proposal and routed to non-GLP-1 alternatives.
Documentation
Every Retatrutide lot ships with a per-batch document pack.
COA, HPLC chromatogram, MS identity confirmation, water content and storage notes. Buyer track and destination confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the Retatrutide reference profile.
Lot traceability
Lot code printed on vial label and reflected in the document pack. Reorders cite the prior lot for continuity.
FAQ
Common Retatrutide questions from B2B buyers.
Why is retatrutide OUS-only?
On 2026-04-30 the FDA proposed removing GLP-1 medications from the 503B bulks list. While retatrutide itself is the target of separate clinical-stage development, PeptiOEM positions it for OUS distribution markets, research, and private-label brand evaluation rather than US compounding.
Which markets do you serve for retatrutide?
Latin America, Southeast Asia, parts of the Middle East, and select EMEA distributors with appropriate local registration.
Can research labs source retatrutide?
Yes — lyophilized retatrutide is supplied for laboratory research with COA, HPLC, and MS. US-bound research inquiries are reviewed against current FDA guidance and the 2026 503B bulks proposal.
What is the MOQ?
Sample lots from 100 vials; production lots from 500 vials with tier pricing.
What does your COA report?
HPLC purity (target ≥99%), MS identity, water content, related-substance profile on request, and lot traceability tied to the document pack.
Related compounds